Bridget Marcellino, MD, PhD is a former CTSA KL2 scholar and now an Assistant Professor in the Tisch Cancer Institute at Mount Sinai specializing in myeloproliferative neoplasms and leukemia. Myeloproliferative Neoplasms are chronic blood disorders that are associated with high morbidity and mortality and have the potential to progress to a form of secondary acute myeloid leukemia which is resistant to standard therapies. As a physician scientist, Dr. Marcellino is committed to the development and preclinical assessment of novel therapies to ultimately allow for improved treatment and cure of patients with these diseases. Currently, the mechanisms driving disease progression in myeloproliferative neoplasms are unclear and the goal of her work is to elucidate these mechanisms enabling identification of novel therapeutic targets for these diseases.
Dr. Marcellino’s laboratory research is specifically focused on understanding how dysregulation of the TP53 pathway and immune dysfunction promote progression of these diseases. Utilizing various models and primary patient specimens, her group is identifying how mutations and overexpression of PPM1D, a key negative regulator of the TP53 pathways, promote expansion of the malignant clone in myeloproliferative neoplasms. Dr. Marcellino’s mentors are Dr. Ronald Hoffman and Dr. John Mascarenhas, both leaders in the field of myeloproliferative neoplasms.
